{
    "clinical_study": {
        "@rank": "141353", 
        "acronym": "LOTUS", 
        "arm_group": {
            "arm_group_label": "Bimatoprost 0.03%", 
            "arm_group_type": "Experimental", 
            "description": "Bimatoprost 0.03% (LUMIGAN\u00ae) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure\n      (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension."
        }, 
        "brief_title": "A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension", 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Glaucoma, Open-Angle", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of open-angle glaucoma or ocular hypertension\n\n          -  No use of Lumigan\u00ae in the past 3 months\n\n        Exclusion Criteria:\n\n          -  Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery\n             within the past 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "289", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061683", 
            "org_study_id": "CN-BIM-0901"
        }, 
        "intervention": {
            "arm_group_label": "Bimatoprost 0.03%", 
            "description": "Bimatoprost 0.03% (LUMIGAN\u00ae) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 12 weeks.", 
            "intervention_name": "Bimatoprost 0.03%", 
            "intervention_type": "Drug", 
            "other_name": "LUMIGAN\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bimatoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China"
                }
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Intraocular Pressure (IOP) in the Study Eye(s)", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061683"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Patients with an Adverse Event of Hyperemia", 
            "safety_issue": "No", 
            "time_frame": "12 Weeks"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}